Treatment strategies for diffusive large B-cell lymphoma
Treatment strategies for diffusive large B-cell lymphoma
复制标题
弥漫性大B细胞淋巴瘤的治疗策略
DOI：
10.15761/orr.1000112
复制
发表时间：
2018
期刊：
影响因子：
--
通讯作者：
William C Cho
中科院分区：
文献类型：
--
作者：
Kong Linling;Zou Linqing;Gu Shiyu;Liu Hong;Song Guoqi;William C Cho
弥漫性大B细胞淋巴瘤（DLBCL）的治疗通常以多药化疗为基础，自20世纪70年代以来，环磷酰胺、长春新碱、阿霉素和泼尼松（CHOP）联合用药已成为DLBCL的标准治疗方法。DLBCL的结果已经通过添加抗CD 20单克隆抗体利妥昔单抗而显著增强。但仍有部分患者一线治疗失败，被认为是复发/难治性DLBCL，需要调整剂量或改变治疗方案。此外，应根据年龄、国际预后指数（IPI）、体能状态、分期、预后评分和免疫组化生物标志物对不同的治疗策略进行分层。此外，许多新药正在研究中，尤其是CAR-T方案将有很大的发展前景。* 联系人：宋国奇，江苏省南通市西四路20号南通大学附属医院血液科，邮编：226001。中国，电子邮件：sdsonggq@163.com William C Cho，中国香港加士居道30号伊利沙伯医院R座临床肿瘤科，电子邮件：chocs@ha.org.hk
The treatment of diffusive large B-cell lymphoma (DLBCL) is generally based on multidrug chemotherapy, the association of cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) has become the standard therapy for DLBCL since the 1970s. The outcome of DLBCL has been substantially enhanced by the addition of the anti-CD20 monoclonal antibody rituximab. However, there is still some patients failed to the first-line treatment, those were considered as relapsed/ refractory DLBCL, and thus we need to adjust the dose or change the therapeutics. In addition, different treatment strategies should be stratified according to age, the International Prognostic Index (IPI), performance status, stage, prognostic score and immunohistochemical biomarkers. Besides, many novel drugs are under investigation in DLBCL patients, especially CAR-T regimen will have great prospects for development. *Correspondence to: Guoqi Song, Department of Hematology, Affiliated Hospital of Nantong University, 20 Xisi Road, Nantong, Jiangsu 226001, P.R. China, E-mail: sdsonggq@163.com William C Cho, Department of Clinical Oncology, Queen Elizabeth Hospital, Block R, 30 Gascoigne Road, Hong Kong, PR China, E-mail: chocs@ha.org.hk
登录
查看更多内容
影响因子：
1.9
作者：
Pejša V;Prka Ž;Lucijanić M;Mitrović Z;Piršić M;Jakšić O;Ajduković R;Kušec R
通讯作者：
Kušec R
影响因子：
4.3
作者：
Lazarus, Hillard M.;Zhang, Mei-Jie;Carreras, Jeanette;Hayes-Lattin, Brandon M.;Ataergin, Asli Selmin;Bitran, Jacob D.;Bolwell, Brian J.;Freytes, Cesar O.;Gale, Robert Peter;Goldstein, Steven C.;Hale, Gregory A.;Inwards, David J.;Klumpp, Thomas R.;Marks, David I.;Maziarz, Richard T.;McCarthy, Philip L.;Pavlovsky, Santiago;Rizzo, J. Douglas;Shea, Thomas C.;Schouten, Harry C.;Slavin, Shimon;Winter, Jane N.;van Besien, Koen;Vose, Julie M.;Hari, Parameswaran N.
通讯作者：
Hari, Parameswaran N.
CD20的表面水平确定抗CD20抗体在体外介导细胞死亡。
影响因子：
3.7
作者：
Singh V;Gupta D;Arora R;Tripathi RP;Almasan A;Macklis RM
通讯作者：
Macklis RM
影响因子：
6.2
作者：
N. Nissen;J. Ersbøll;H. S. Hansen;S. Walbom-jørgensen;J. Pedersen‐Bjergaard;M. Hansen;J. Rygård
通讯作者：
N. Nissen;J. Ersbøll;H. S. Hansen;S. Walbom-jørgensen;J. Pedersen‐Bjergaard;M. Hansen;J. Rygård
影响因子：
0.9
作者：
C. Calderón‐Cabrera;F. Márquez‐Malaver;F. de la Cruz-Vicente;F. Falantes;E. Carrillo;R. Parody;I. Montero;J. González Campos;M. Martino;M. Carmona;J. Pérez-Simón;I. Espigado
通讯作者：
C. Calderón‐Cabrera;F. Márquez‐Malaver;F. de la Cruz-Vicente;F. Falantes;E. Carrillo;R. Parody;I. Montero;J. González Campos;M. Martino;M. Carmona;J. Pérez-Simón;I. Espigado